Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (3054)	5/27/1999 9:31:00 AM
From: chirodoc	Respond to of 10280

drugs are out of favor, sepr is out of favor....... any time you can buy a drug company with this many drugs in the pipeline, with such an efficient FDA preparation process 50% below its high (albeit the high was a bit inflated),there is market capitulation. i am still buying this company and look forward to a stock price in 1-2 years that will make me smile. as a chiropractor i treat thousands of patients every year. i guarantee you they will choose a drug with less side effects over one with more, they will choose oral before injection--anyday. even without a great sales force, this company will continue to add to the market, every year, a drug or two that will have less side effects than a competitor. forget all of the new drugs coming to market as a huge threat. most patients still take motrin and will continue to take drugs that they feel are safe, easy-to-take and effective. this will be a powerful drug company in 5 years. i am also buying more pfizer--what a gift. curtis

To: BMcV who wrote (3054)	5/27/1999 9:36:00 AM
From: Biomaven	Read Replies (2) \| Respond to of 10280

I agree with several thread participants that the IgE story has nothing to do with SEPR's weakness. If this was perceived as a serious threat to the antihistamine market, we would have seen major weakness in SGP compared with the other pharmas. This has clearly not been the case: techstocks.com For an example of the superficial "analysis" that has helped drive the stock down, let me offer this, quoted from a glowing article in TheStreet by Herb Greenberg (who usually knows better) about one Jordan Kimmel, president of Magnet Investing in TheStreet: Then there was the time, shortly after he called on McKesson, that he sent out a warning about Sepracor (SEPR:Nasdaq), the now-fallen biotech giant, which lost its air after Johnson & Johnson (JNJ:NYSE) chose not to exercise its option to co-promote a new version of Sepracor's allergy drug. "It had high debt, extremely decreased revenues, insiders didn't own a share and somehow this stock was going up because of momentum players. As soon as the momentum broke, I went short." Peter